KRAS and cholangiocarcinoma: For instance, results of contemporary clinical trials investigating FGFR2 inhibition in cholangiocarcinoma, including infigratinib (NCT03773302) and futibatinib (NCT04093362), could perhaps be extrapolated to patients with FGFR2 fusion positive, KRAS wildtype PDAC.